Key result
Cardiac glycosides modulate Na+/K+-ATPase signaling and may enhance the cytotoxicity of conventional anti-cancer drugs.
Why the study?
Cardiac glycosides may alter the efficiency of chemotherapeutic agents by modulating cancer cell death, but their effects in combination with drugs like cisplatin and etoposide are not fully understood.
Cardiac glycosides (CGs) or cardiotonic steroids, which constitute a group of naturally occurring compounds with a steroid-like structure, can act on Na+/K+-ATPase as a receptor and activate intracellular signaling messengers leading to a variety of cellular responses. Epidemiological studies have revealed that CGs, used for the treatment of cardiac disorders, may also be beneficial as anti-cancer agents. CGs, acting in combination with other chemotherapeutic agents, may significantly alter their efficiency in relation to cancer cell elimination, causing both sensitization and an increase in cancer cell death, and in some cases resistance to chemotherapy. Here we show the ability of CGs to modulate apoptotic response to conventionally used anti-cancer drugs. In combination with etoposide, CGs digoxin may enhance cytotoxic potential, thereby allowing the chemotherapeutic dose to be decreased and minimizing toxicity and adverse reactions. Mechanisms behind this event are discussed.
No takes yet. Share an insight, caveat, or question.
Kulikov et al. (2016) reported a review. Cardiac glycosides was evaluated. Cardiac glycosides can act on the Na+/K+-ATPase to modulate intracellular signaling and may enhance the cytotoxic potential of conventionally used anti-cancer drugs such as etoposide.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: